<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.115324</article-id><article-id pub-id-type="publisher-id">ACM-42572</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210500000_84410831.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  肾性贫血发生机制的研究现状
  Research Status of the Mechanism of Renal Anemia
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>倩</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>巴</surname><given-names>应贵</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff3"><addr-line>青海大学附属医院肾内科，青海 西宁</addr-line></aff><aff id="aff2"><addr-line>青海大学研究生院，青海 西宁</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>08</day><month>05</month><year>2021</year></pub-date><volume>11</volume><issue>05</issue><fpage>2251</fpage><lpage>2256</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  贫血是慢性肾脏病(Chronic Kidney Disease, CKD)常见的并发症之一，由于各种原因导致的肾功能损害引起的红系生长因子，即促红细胞生成素(Erythropoietin, EPO)的缺乏是最主要的原因，当然还有一些毒性物质的蓄积也参与了贫血的发生。贫血的发生显著提高了患者的就诊次数及住院率，心血管事件的发生率和死亡率。有研究显示，目前在我国，有1.2亿人患有慢性肾脏疾病，预计可能还会增加。相应地贫血的发生率也会随之增加。目前对于肾性贫血治疗的达标率还不理想，因此，明确肾性贫血的机制有助于为肾性贫血的治疗提供思路。本文就肾性贫血发病机制作一综述。
   Anemia is one of the common complications of Chronic Kidney Disease (CKD). The lack of erythropoietin (EPO) caused by renal damage caused by various reasons is the main reason for this anemia. The occurrence of anemia significantly increases the number of visits and hospitalizations, the incidence and mortality of cardiovascular events. Studies have shown that there are 120 million people suffering from chronic kidney disease in my country, and it is expected to increase. Correspondingly, the incidence of anemia will also increase. At present, the rate of reaching the standard for the treatment of renal anemia is not ideal. Therefore, clarifying the mechanism of renal anemia helps to provide ideas for the treatment of renal anemia. This article summarizes the pathogenesis of renal anemia.
 
</p></abstract><kwd-group><kwd>肾性贫血，发病机制，慢性肾脏病, Renal Anemia</kwd><kwd> Pathogenesis</kwd><kwd> Chronic Kidney Disease</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>贫血是慢性肾脏病(Chronic Kidney Disease, CKD)常见的并发症之一，由于各种原因导致的肾功能损害引起的红系生长因子，即促红细胞生成素(Erythropoietin, EPO)的缺乏是最主要的原因，当然还有一些毒性物质的蓄积也参与了贫血的发生。贫血的发生显著提高了患者的就诊次数及住院率，心血管事件的发生率和死亡率。有研究显示，目前在我国，有1.2亿人患有慢性肾脏疾病，预计可能还会增加。相应地贫血的发生率也会随之增加。目前对于肾性贫血治疗的达标率还不理想，因此，明确肾性贫血的机制有助于为肾性贫血的治疗提供思路。本文就肾性贫血发病机制作一综述。</p></sec><sec id="s2"><title>关键词</title><p>肾性贫血，发病机制，慢性肾脏病</p></sec><sec id="s3"><title>Research Status of the Mechanism of Renal Anemia<sup> </sup></title><p>Qian Zhang<sup>1</sup>, Yinggui Ba<sup>2*</sup></p><p><sup>1</sup>Graduate School of Qinghai University, Xining Qinghai</p><p><sup>2</sup>Department of Nephrology, Affiliated Hospital of Qinghai University, Xining Qinghai</p><p><img src="//html.hanspub.org/file/33-1572208x5_hanspub.png" /></p><p>Received: Apr. 21<sup>st</sup>, 2021; accepted: May 7<sup>th</sup>, 2021; published: May 26<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/33-1572208x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Anemia is one of the common complications of Chronic Kidney Disease (CKD). The lack of erythropoietin (EPO) caused by renal damage caused by various reasons is the main reason for this anemia. The occurrence of anemia significantly increases the number of visits and hospitalizations, the incidence and mortality of cardiovascular events. Studies have shown that there are 120 million people suffering from chronic kidney disease in my country, and it is expected to increase. Correspondingly, the incidence of anemia will also increase. At present, the rate of reaching the standard for the treatment of renal anemia is not ideal. Therefore, clarifying the mechanism of renal anemia helps to provide ideas for the treatment of renal anemia. This article summarizes the pathogenesis of renal anemia.</p><p>Keywords:Renal Anemia, Pathogenesis, Chronic Kidney Disease</p><disp-formula id="hanspub.42572-formula49"><graphic xlink:href="//html.hanspub.org/file/33-1572208x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/33-1572208x8_hanspub.png" /> <img src="//html.hanspub.org/file/33-1572208x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 肾性贫血的发病机制</title><sec id="s5_1"><title>1.1. 促红细胞生成素不足</title><p>促红细胞生成素是一种传统意义上的造血生长因子，其主要的生物学作用是促进红细胞的生成 [<xref ref-type="bibr" rid="hanspub.42572-ref1">1</xref>]。EPO主要参与调控后祖细胞的增殖活化，这是因为大多数后祖细胞的表面存在EPO的受体，而前祖细胞表达有EPO受体的部分仅仅占20% [<xref ref-type="bibr" rid="hanspub.42572-ref2">2</xref>]。EPO与祖细胞EPO受体结合之后，EPO受体被磷酸化，经过一系列复杂的过程使得网织红细胞的数量不断增多并且释放入血 [<xref ref-type="bibr" rid="hanspub.42572-ref3">3</xref>]。在严重缺氧情况下，EPO生成明显增加，最终红细胞生成增多。慢性肾脏病中晚期随着肾功能的逐渐减退，肾实质的逐渐萎缩，肾脏对低氧的反应性减低，通过肾脏产生的EPO越来越少，不能够满足机体的需要，从而导致贫血的发生，在后期贫血进行性加重，这不但增加了患者的医疗负担，甚至威胁到患者的生命。目前临床上广泛使用重组人促红细胞生成素(rHuEPO)来改善肾功能不全患者的贫血，进一步说明了EPO产生不足是导致肾性贫血的关键原因。</p></sec><sec id="s5_2"><title>1.2. 慢性炎症</title><sec id="s5_2_1"><title>1.2.1. 微炎症状态是CKD患者的特有标签</title><p>许多固有免疫细胞分布于肾脏，它们维护着肾脏的内部平衡。一旦被某些因素激活，这些细胞在产生炎症介质的同时损伤了肾脏，并同时打破了肾脏的这种平衡 [<xref ref-type="bibr" rid="hanspub.42572-ref4">4</xref>]。随着CKD进行性发展，相应的肾细胞的损害更严重，CKD患者的慢性炎症状态随着体内多种炎性因子水平的增加而逐渐加重 [<xref ref-type="bibr" rid="hanspub.42572-ref5">5</xref>]。当然也加速了CKD的进展 [<xref ref-type="bibr" rid="hanspub.42572-ref6">6</xref>]。炎症因子进一步影响肾脏再灌注、导致血管内皮损伤，从而导致CKD持续进展 [<xref ref-type="bibr" rid="hanspub.42572-ref7">7</xref>]。因此，炎症水平的控制对于肾性贫血的治疗意义重大，EPO治疗肾性贫血受炎症水平的影响，亟待一种新的不受炎症影响的新药物的问世。</p></sec><sec id="s5_2_2"><title>1.2.2. 炎症可通过各种路径导致肾性贫血的发生及进展</title><p>炎症对于骨髓红系增殖有明显的抑制作用，缩减了红细胞的寿命从而贫血 [<xref ref-type="bibr" rid="hanspub.42572-ref8">8</xref>]。如前所述，患者体内炎症因子抑制骨髓造血多个阶段及红细胞各个阶段合成以及增殖和分化，这抑制了内源性促红细胞生成素的生成，导致红细胞的生成减少 [<xref ref-type="bibr" rid="hanspub.42572-ref9">9</xref>]。甚至在全身炎症状态下，红细胞膜的脂质重塑过程也受到影响，红细胞的产生被抑制。另外，炎症导致加速清除红细胞的物质的数量增加，降低了红细胞的存活率，引起贫血的发生 [<xref ref-type="bibr" rid="hanspub.42572-ref10">10</xref>]。有研究结果显示，炎症水平对血红蛋白水平有抑制作用 [<xref ref-type="bibr" rid="hanspub.42572-ref11">11</xref>]。更有研究发现，血液透析患者中EPO抵抗发生与炎症水平相关。这表明，炎症是EPO反应低下的高危因素。或许我们可以根据CRP的水平来判断EPO抵抗的发生 [<xref ref-type="bibr" rid="hanspub.42572-ref12">12</xref>]。综上，我们可以得出，通过控制CKD患者体内炎症状态，增加EPO的反应性，可以改善肾性贫血，从而为肾性贫血的治疗提供一种新的思路。炎症诱导铁调素水平升高，降低机体对铁的利用；铁是人体重要的元素之一，是红细胞生成必不可少的原料，铁的水平降低，必然会影响到红细胞的生成。铁在我们体内的代谢经历吸收、转运、运用、储存等四个环节，当然上述的各种过程都离不开各种酶的作用。吸收的铁少部分留着自身代谢和贮存，绝大部分通过膜铁转运蛋白(FPN)转运入全身血液循环供机体利用。炎症影响铁的吸收，在炎症状态下，铁调素的生成增加，使得铁的转运途径发生了改变，铁储备的动员下降，使得铁被困于细胞内，从而储存铁无法与循环中的转铁蛋白结合，导致贫血的发生。</p></sec></sec><sec id="s5_3"><title>1.3. 铁调素表达增多</title><p>铁调素 [<xref ref-type="bibr" rid="hanspub.42572-ref13">13</xref>] 由肝脏产生和代谢，膜铁转运蛋白(ferroportin, FPN)是其发挥作用的载体，是控制体内铁代谢的枢纽。诸多因素影响了铁调素的生成及表达。铁调素作为铁代谢的关键控制因子，受细胞内贮存铁和转铁蛋白铁浓度的影响。机体贮存铁过多及体内炎症状态情况下，铁调素的表达上调；贫血和缺氧的条件下可发生铁调素表达抑制。炎症因子促进铁调素基因的表达可以通过诱导激活某种信号传导，这种信号传导作用的方式不同，上调铁调素表达的途径不同 [<xref ref-type="bibr" rid="hanspub.42572-ref14">14</xref>]。铁调素增多，铁的利用出现障碍，而引起贫血的发生。因此铁调素抑制剂或许在肾性贫血的治疗中扮演着重要的角色。</p></sec><sec id="s5_4"><title>1.4. 维生素D代谢紊乱</title><p>大部分CKD患者存在维生素D水平低下，有研究发现 [<xref ref-type="bibr" rid="hanspub.42572-ref15">15</xref>]，ESRD患者发生贫血与维生素D有莫大关联。因此，外源性的补充维生素D可能是治疗肾性贫血的另一种新方法。维生素D的主要作用是调节钙磷平衡。因此，维生素D的活化与体内PTH浓度、高血磷和低血钙之间存在着反馈作用。继发甲状旁腺功能亢进引起贫血的可能机制 [<xref ref-type="bibr" rid="hanspub.42572-ref16">16</xref>] 为对于红系祖细胞的产生和分化的抑制及增加红细胞膜的脆性，从而缩短红细胞寿命加重贫血。有研究表明，维生素D可通过抑制炎症细胞因子及铁调素表达来促进红细胞生成 [<xref ref-type="bibr" rid="hanspub.42572-ref17">17</xref>]。还有报道，CKD肾性贫血患者，通过补充活性维生素D而改善了贫血，而且意外的发现EPO的使用剂量也随之降低 [<xref ref-type="bibr" rid="hanspub.42572-ref18">18</xref>]。维生素D除了上述作用外，对抗炎症因子的作用也不容忽视 [<xref ref-type="bibr" rid="hanspub.42572-ref19">19</xref>]。1, 25( OH)2 D与维生素D受体结合后，导致铁调素表达抑制 [<xref ref-type="bibr" rid="hanspub.42572-ref20">20</xref>]。这说明，维生素D可下调铁调素水平从而影响肾性贫血。但是随后的研究发现，维生素D3可直接调节铁调素的表达，当然是在健康人群中，这一过程并不依赖铁调素 [<xref ref-type="bibr" rid="hanspub.42572-ref21">21</xref>]。还有研究证明，服用骨化三醇对于血清铁调素水平并未抑制 [<xref ref-type="bibr" rid="hanspub.42572-ref22">22</xref>]。综上，维生素D与肾性贫血的关系是错综复杂的，目前还未能完全阐明，未来的探索道路任重而道远。</p></sec><sec id="s5_5"><title>1.5. 成纤维细胞生长因子-23</title><p>成纤维细胞生长因子23 (fibroblast growth factor 23, FGF23)是一种钙磷调节激素，主要由骨骼中的骨细胞和成骨细胞分泌。CKD进展时，随着肾功能的逐步丢失，矿物质和骨代谢发生紊乱，随着肾小球滤过率的不断下降，从肾小球滤过的磷减少，血磷有升高趋势。最近的研究显示，血磷升高，为了抑制体内的这种紊乱，FGF23的分泌就增加，FGF23的重要作用之一就是减少肾小管对磷的重吸收。有研究表明，FGF23抑制红细胞的生成及活化 [<xref ref-type="bibr" rid="hanspub.42572-ref23">23</xref>]。更有报道，FGF23水平升高，贫血越严重。由此，可抑制FGF23的表达来促进红细胞的生成，而且还可减轻炎症，抑制铁调素的表达，升高血清铁的水平 [<xref ref-type="bibr" rid="hanspub.42572-ref24">24</xref>]。综上，关于FGF23对于肾性贫血的影响是明确的，FGF23抑制红细胞的生成。但是FGF23对于炎症水平及铁调素水平的表达目前相关的研究较少，以后尚需更多的临床研究及数据来支撑。</p></sec><sec id="s5_6"><title>1.6. 红细胞生成抑制因子</title><p>CKD患者随着病程的不断进展，体内的毒素水平升高，毒素排泄明显下降，血液净化方式也无法有效清除。甲状旁腺激素(PTH)对于肾性贫血的影响目前研究颇多，有研究已经证实，甲状旁腺次全切除术后尿毒症患者贫血能够得到显著改善。并且甲状旁腺次全切除术治疗继发性甲状旁腺功能亢进症的效果明显优于药物 [<xref ref-type="bibr" rid="hanspub.42572-ref25">25</xref>]。慢性肾脏病的患者食欲下降或饮食控制，钙摄入减少，同时随着肾脏结构的不断进展，肾脏损伤越严重，活性维生素D缺乏，更为重要的是胃肠道对钙吸收能力减退，从而出现低钙血症。低钙血症刺激PTH合成和分泌，PTH又作用于肾小管，升高血钙水平，从而使血钙水平趋向正常。但是随着肾功能的不断进展，PTH失代偿状态，无法再逆转此种代谢紊乱，PTH在患者体内的水平升高。激活钙泵活性，此时细胞内高钙，破坏红细胞膜导致贫血。PTH还能抑制红细胞能量的生成过程，影响红细胞的供能。PTH还可使机体一直处于炎症状态 [<xref ref-type="bibr" rid="hanspub.42572-ref26">26</xref>]。综上所述，不同分子量的毒性产物，可能通过抑制骨髓祖细胞的多个阶段、抑制红细胞生成的信号通路及增加红细胞的渗透脆性、减少能量供应等多个途径抑制红细胞的生成。关于尿毒症毒素水平对于肾性贫血的影响可涉及多种机制，机制复杂，目前还未完全阐明，还有待进一步的深入研究。</p></sec><sec id="s5_7"><title>1.7. 其他因素</title><p>不同的静脉通路也会影响贫血的发生及发展，带卡夫的中心静脉导管由于是异物，长期留置人体一方面加重尿毒症患者原有炎症状态，另一方面导管由于护理不当或别的各种原因容易发生感染，透析时由于凝血部分血液残留在管路，从而加重贫血。总之，使用自体动静脉内瘘才是透析患者保驾护航的基础。肾衰竭患者因容量依懒性或者肾素依赖性的紊乱，可有不同程度高血压的存在，寻找降压药物的脚步一直没有停歇，RAS阻滞剂因其卓越的对于心功能及心肌重构方面的作用，更兼具降压、降低尿蛋白而常作为CKD患者的降压药的最佳选择。血管紧张素II有刺激EPO生成的作用，使用RAS阻滞剂可能抑制EPO生成，从而导致贫血加重。心脏前后负荷增加时，心肌细胞分泌脑钠肽(BNP)及NT-proBNP水平增加 [<xref ref-type="bibr" rid="hanspub.42572-ref27">27</xref>]。贫血时，由于左心室的代偿作用，导致左心室肥厚，BNP的分泌增加。这表明随着贫血的加重，血NT-proBNP水平随之升高。所以，在纠正肾性贫血的同时，也要考虑到容量的影响因素。肾功能障碍的患者，有很大的失血风险，这些风险主要来自透析，尤其是血液透析。每次透析结束后透析管路中残留血及定期抽血监测各种指标失血。这些无疑使肾性贫血患者雪上加霜。CKD患者凝血障碍及血小板功能低下，更加重贫血。CKD患者由于尿毒症毒素在体内积蓄导致胃肠粘膜水肿，导致纳差、恶心、呕吐。造血原料吸收障碍，引起贫血。慢性肾衰竭时，铁的缺乏十分常见，各种原因可造成缺铁，由于饮食铁含量不足及胃肠道吸收被干扰导致的铁摄入不足，血液透析病人每年丢失3~5 g铁，比没有肾脏功能障碍的患者高出10~20倍 [<xref ref-type="bibr" rid="hanspub.42572-ref28">28</xref>]。左卡尼汀即左旋肉碱，是三羧酸循环中重要的载体。左卡尼汀缺乏时，三羧酸循环出现障碍，导致能量供应不足。肾衰竭时体内左旋肉碱缺乏，导致细胞内能量缺乏，导致贫血及营养不良的发生。因此，在肾性贫血治疗时，左卡尼汀的辅助作用不能忽视。</p></sec></sec><sec id="s6"><title>2. 小结</title><p>贫血几乎累及CKD5期所有的患者，目前对于它的发病机制还未完全阐明。红系生长因子的相对或绝对缺乏是主要原因，但是炎症通过缩减红细胞寿命，增加铁调素水平表达等多种途径导致贫血的发生，铁调素表达上调使铁利用出现障碍，从而加重贫血，FGF-23及尿素症毒素抑制红细胞的生成及寿命。造血原料缺乏及营养不良、不同的静脉通路、RAS阻滞剂等都参与了肾性贫血的发生。综上，肾性贫血的发生是多因素共同产生的结果。因此，明确它的发病机制可以为治疗提供依据，目前比较传统的治疗方法就是ESA联合铁剂，但是二者在治疗过程中也面临着多种问题，如易引起血压水平升高，ESA抵抗，铁剂容易过敏等；更重要的是，目前肾性贫血的治疗率未达标。随着研究的不断深入，一些新的药物进入我们的视野。在低氧条件下发挥作用的低氧诱导因子脯氨酰羟化酶抑制剂目前已在我国上市，铁调素抑制剂、EPO基因治疗、FGF-23抑制剂目前也正在研究中，我们有理由相信，随着新药物的问世，会为肾性贫血的治疗带来可喜的改变，为肾性贫血患者带来曙光，减少并发症的发生，提高患者的生活质量乃至生存时间。</p></sec><sec id="s7"><title>文章引用</title><p>张 倩,巴应贵. 肾性贫血发生机制的研究现状Research Status of the Mechanism of Renal Anemia[J]. 临床医学进展, 2021, 11(05): 2251-2256. https://doi.org/10.12677/ACM.2021.115324</p></sec><sec id="s8"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.42572-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Cernaro, V., et al. (2019) Erythropoiesis and Chronic Kidney Disease-Related Anemia: From Physiology to New Therapeutic Advancements. Medicinal Research Reviews, 39, 427-460.</mixed-citation></ref><ref id="hanspub.42572-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">李青. 肾性贫血的机制和治疗研究现状[D]: [硕士学位论文]. 南昌: 南昌大学, 2017.</mixed-citation></ref><ref id="hanspub.42572-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Fisher, J.W. (2003) Erythropoietin: Physiology and Pharmacology Update. Experimental Biology and Medicine, 228, 1-14. &lt;br&gt;https://doi.org/10.1177/153537020322800101</mixed-citation></ref><ref id="hanspub.42572-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">刘颖, 林洪丽. 慢性肾脏病贫血与炎症[J]. 中国实用内科杂志, 2020, 40(11): 908-911.</mixed-citation></ref><ref id="hanspub.42572-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Mihai, S., Codrici, E., Popescu, I.D., et al. (2018) Inflammation Related Mechanisms in Chronic Kidney Disease Prediction, Progression, and Outcome. Journal of Immunology Research, 2018, Article ID: 2180373.  
&lt;br&gt;https://doi.org/10.1155/2018/2180373</mixed-citation></ref><ref id="hanspub.42572-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">赵璐, 刘虹. 慢性肾脏病患者的炎症状态及其对肾性贫血治疗的影响[J]. 中国血液净化, 2020, 19(3): 149-152.</mixed-citation></ref><ref id="hanspub.42572-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Eustace, J.A., Astor, B., Muntner, P.M., et al. (2004) Prevalence of Acidosis and Inflammation and Their Association with Low Serum Albumin in Chronic Kidney Disease. Kidney International, 65, 1031-1040.  
&lt;br&gt;https://doi.org/10.1111/j.1523-1755.2004.00481.x</mixed-citation></ref><ref id="hanspub.42572-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Sproston, N.R. and Ashworth, J.J. (2018) Role of C-Reactive Protein at Sites of Inflammation and Infection. Frontiers in Immunology, 9, 754. &lt;br&gt;https://doi.org/10.3389/fimmu.2018.00754</mixed-citation></ref><ref id="hanspub.42572-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Hom, J., Dulmovits, B.M., Mohandas, N., et al. (2015) The Erythroblastic Island as an Emerging Paradigm in the Anemia of Inflammation. Immunologic Research, 63, 75-89. &lt;br&gt;https://doi.org/10.1007/s12026-015-8697-2</mixed-citation></ref><ref id="hanspub.42572-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Dinkla, S., Vaneijk, L.T., Fuchs, B., et al. (2016) Inflammation-Associated Changes in Lipid Composition and the Organization of the Erythrocyte Membrane. BBA Clinical, 5, 186-192. &lt;br&gt;https://doi.org/10.1016/j.bbacli.2016.03.007</mixed-citation></ref><ref id="hanspub.42572-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Karaboyas, A., Morgenstern, H., Fleischer, N.L., et al. (2020) Inflammation and Erythropoiesis-Stimulating Agent Response in Hemodialysis Patients: A Self-Matched Longitudinal Study of Anemia Management in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Kidney Medicine, 2, 286-296.  
&lt;br&gt;https://doi.org/10.1016/j.xkme.2020.01.007</mixed-citation></ref><ref id="hanspub.42572-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Kimachi, M., Fukuma, S., Yamazaki, S., et al. (2015) Minor Elevation in C-Reactive Protein Levels Predicts Incidence of Erythropoiesis-Stimulating Agent Hyporesponsiveness among Hemodialysis Patients. Nephron, 131, 123-130.  
&lt;br&gt;https://doi.org/10.1159/000438870</mixed-citation></ref><ref id="hanspub.42572-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Mccullough, K. and Bolisetty, S. (2020) Ferritins in Kidney Disease. Seminars in Nephrology, 40, 160-172.  
&lt;br&gt;https://doi.org/10.1016/j.semnephrol.2020.01.007</mixed-citation></ref><ref id="hanspub.42572-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Ueda, N. and Takasawa, K. (2018) Impact of Inflammation on Ferritin, Hepcidin and the Management of Iron Deficiency Anemia in Chronic Kidney Disease. Nutrients, 10, 1173. &lt;br&gt;https://doi.org/10.3390/nu10091173</mixed-citation></ref><ref id="hanspub.42572-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Kim, Y.L., Kim, H., Kwon, Y.E., et al. (2016) Association between Vitamin D Deficiency and Anemia in Patients with End-Stage Renal Disease: A Cross-Sectional Study. Yonsei Medical Journal, 57, 1159-1164.  
&lt;br&gt;https://doi.org/10.3349/ymj.2016.57.5.1159</mixed-citation></ref><ref id="hanspub.42572-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">朱丽娇, 徐承云, 刘欣, 等. 慢性肾脏病患者甲状旁腺激素与肾性贫血的关系[J]. 广东医学, 2018, 39(14): 2232-2235.</mixed-citation></ref><ref id="hanspub.42572-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">肖宇, 王洁. 肾性贫血发生机制的研究进展[J]. 广西医学, 2020, 42(2): 198-202.</mixed-citation></ref><ref id="hanspub.42572-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Yin, K. and Agrawal, D.K. (2014) Vitamin D and Inflammatory Diseases. Inflammation Research, 7, 69-87.  
&lt;br&gt;https://doi.org/10.2147/JIR.S63898</mixed-citation></ref><ref id="hanspub.42572-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">张燕丽, 卜玲芝, 敬小青. 儿童维生素D水平与脓毒症的相关性[J]. 世界最新医学信息文摘, 2019, 19(20): 38-39.</mixed-citation></ref><ref id="hanspub.42572-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">刘烨歆, 刘虹. 慢性肾脏病患者维生素D缺乏与贫血的关系[J]. 中国血液净化, 2016(11): 620-623.</mixed-citation></ref><ref id="hanspub.42572-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Smith, E.M., Alvarez, J.A., Kearns, M.D., et al. (2017) High-Dose Vitamin D3 Reduces Circulating Hepcidin Concentrations: A Pilot, Randomized, Double-Blind, Placebo-Controlled Trial in Healthy Adults. Clinical Nutrition, 36, 980-985.  
&lt;br&gt;https://doi.org/10.1016/j.clnu.2016.06.015</mixed-citation></ref><ref id="hanspub.42572-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Panwar, B., McCann, D., Olbina, G., et al. (2018) Effect of Calcitriol on Serum Hepcidin in Individuals with Chronic Kidney Disease: A Randomized Controlled Trial. BMC Nephrology, 19, 35.  
&lt;br&gt;https://doi.org/10.1186/s12882-018-0823-7</mixed-citation></ref><ref id="hanspub.42572-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Daryadel, A., Bettoni, C., Haider, T., et al. (2018) Erythropoietin Stimulates Fibroblast Growth Factor 23 (FGF23) in Mice and Men. Pflügers Archiv, 470, 1569-1582. &lt;br&gt;https://doi.org/10.1007/s00424-018-2171-7</mixed-citation></ref><ref id="hanspub.42572-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Agoro, R., Montagna, A., Goetz, R., et al. (2018) Inhibition of Fibro-Blast Growth Factor 23 (FGF23) Signaling Rescues Renal Anemia. FASEB Journal, 32, 3752-3764. &lt;br&gt;https://doi.org/10.1096/fj.201700667R</mixed-citation></ref><ref id="hanspub.42572-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">沈英, 张萍, 蒋华, 等. 甲状旁腺切除对尿毒症继发甲状旁腺功能亢进患者贫血和心功能的影响[J]. 中华肾脏病杂志, 2018, 34(5): 321-326.</mixed-citation></ref><ref id="hanspub.42572-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Cueff, A., Seear, R., Dyrda, A., Bouyer, G., Egee, S., Esposito, A., et al. (2010) Effects of Elevated Intracellular Calcium on the Osmotic Fragility of Human Red Blood Cells. Cell Calcium, 47, 29-36.  
&lt;br&gt;https://doi.org/10.1016/j.ceca.2009.11.002</mixed-citation></ref><ref id="hanspub.42572-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">毛永辉, 赵班, 陈欢, 等. 腹膜透析患者血清N末端前体脑钠肽水平的变化及影响因素探讨[J]. 中国血液净化, 2014, 13(10): 717-721.</mixed-citation></ref><ref id="hanspub.42572-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Kutuby, F., Wang, S., Desai, C. and Lerma, E.V. (2015) Anemia of Chronic Kidney Disease. Disease-a-Month, 61, 421-424. &lt;br&gt;https://doi.org/10.1016/j.disamonth.2015.08.002</mixed-citation></ref></ref-list></back></article>